|本期目录/Table of Contents|

[1]杨雅玲,刘华斌,林庆金.枸橼酸坦度螺酮治疗帕金森病异动症的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):146-150.[doi:10.3969/j.issn.1672-271X.2021.02.008]
　YANG Ya-ling,LIU Hua-bin,LIN Qing-jin.Therapeutic effect of tandorone citrate on Parkinson’s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(02):146-150.[doi:10.3969/j.issn.1672-271X.2021.02.008]
点击复制

枸橼酸坦度螺酮治疗帕金森病异动症的疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年02期
页码:
146-150
栏目:
临床研究
出版日期:
2021-03-22

文章信息/Info

Title:
Therapeutic effect of tandorone citrate on Parkinson’s disease
作者:
杨雅玲; 刘华斌; 林庆金
363000漳州，解放军联勤保障部队第九○九医院(厦门大学附属东南医院)神经内科（杨雅玲、刘华斌、林庆金）
Author(s):
YANG Ya-ling;  LIU Hua-bin;  LIN Qing-jin
（Department of Neurology, the 909th Hospital of the Joint Logistics Support Force，PLA, Zhangzhou 363000, Fujian， China）
关键词:
帕金森病; 异动症; 枸橼酸坦度螺酮; 氯氮平
Keywords:
Parkinson’s disease;  dyskinesia;  tandospirone citrate;  clozapine
分类号:
R742.5
DOI:
10.3969/j.issn.1672-271X.2021.02.008
文献标志码:
A
摘要:
目的探讨枸橼酸坦度螺酮治疗左旋多巴诱导的异动症的临床疗效。方法回顾性分析182例帕金森病异动症患者的临床资料，所有患者均应用左旋多巴及多巴胺受体激动剂作为帕金森病基础治疗。根据是否服用枸橼酸坦度螺酮或氯氮平分为4组：联用组：同时使用枸橼酸坦度螺酮和氯氮平；枸橼酸坦度螺酮组：仅使用枸橼酸坦度螺酮；氯氮平组：仅使用氯氮平；对照组：未使用枸橼酸坦度螺酮和氯氮平。经过12周治疗后，以统一帕金森病评定量表（UPDRS）各部分评分相对治疗前基线水平的变化为指标评估疗效。结果治疗12周后，联用组、枸橼酸坦度螺酮组、氯氮平组、对照组治疗后日常生活能力评分（6.79±5.09、8.06±3.71、8.13±4.81、9.45±3.23）、运动功能评分（12.88±8.50、13.89±6.94、14.18±10.84、17.25±6.80）较基线水平(13.98±5.25、13.86±3.18、13.31±5.45、13.18±3.61；26.98±11.33、26.18±4.58、26.82±8.92、26.53±8.26)均有显著改善（P＜0.05）。联用组、枸橼酸坦度螺酮组、氯氮平组治疗后的异动症评分（2.55±1.77、3.42±1.94、3.51±2.44）及异动症持续时间[（1.80±1.59、2.69±2.10、2.66±1.95）h]相对基线水平[(7.38±2.23、7.20±1.66、7.47±2.23)；（7.54±2.20、7.19±2.10、7.38±2.43）h]均显著下降（P＜0.05），与对照组相比，联用组、枸橼酸坦度螺酮组及氯氮平组异动症评分及持续时间进一步改善，差异有统计学意义（P＜0.05）。联用组治疗后的异动症评分及异动症持续时间与枸橼酸坦度螺酮组和氯氮平组相比分值进一步降低，差异有统计学意义（P＜0.05）。4组的总有效率分别为95.2%、85.5%、84.4%和30.0%。4组的不良反应发生率分别为28.6%、23.6%、24.4%和25.0%，差异无统计学意义（P＞0.05）。结论枸橼酸坦度螺酮可减轻帕金森病患者异动症状，值得临床推广应用，对于症状严重者，可考虑与氯氮平联用。
Abstract:
ObjectiveTo investigate the clinical effect oftandospirone citrate in the treatment of levodopa induced dyskinesia. MethodsA total of 182 patients with Parkinson’s disease were analyzed retrospectively. Levodopa and dopamine receptor agonists were used as the basic treatment of Parkinson’s disease in all cases. The cases were grouped and compared as follows, group 1: simultaneous use of tandospirone and clozapine; group 2: use tandospirone only; group 3: use clozapine only; group 4: do not use tandospirone and clozapine. After 12 weeks of treatment, the effect was evaluated by the changes of the scores of each part of the Unified Parkinson’s Disease Rating Scale (UPDRS) compared with the baseline level before treatment. ResultsAfter 12 weeks of treatment, the scores of daily living function (6.79±5.09，8.06±3.71，8.13±4.81，9.45±3.23) and motor function (12.88±8.50，13.89±6.94，14.18±10.84，17.25±6.80) in all groups were significantly improved compared with the baseline level (13.98±5.25，13.86±3.18，13.31±5.45，13.18±3.61; 26.98±11.33，26.18±4.58，26.82±8.92，26.53±8.26; P<0.05). In the simultaneous use of tandospirone and clozapine group, tandospirone only group and clozapine only group, the score of dyskinesia (2.55±1.77，3.42±1.94，3.51±2.44) and duration of dyskinesia [(1.80±1.59，2.69±2.10，2.66±1.95)h] decreased significantly compared with the baseline level [(7.38±2.23，7.20±1.66，7.47±2.23); (7.54±2.20，7.19±2.10，7.38±2.43)h; P<0.05], compared with the group without tandospirone and clozapine. The score and duration of dyskinesia were improved significantly (P<0.05). The scores of dyskinesia and duration of dyskinesia in the simultaneous use of tandospirone and clozapine group were lower than those in tandospirone group and clozapine group (P<0.05). The total effective rates of the four groups were 95.2%，85.5%，84.4% and 30.0%, respectively. The incidence of adverse reactions was 28.6%，23.6%，24.4% and 25.0%, respectively (P>0.05).ConclusionTanduluone citrate tablets can alleviate the abnormal movement of Parkinson’s disease and is worthy of clinical application. For those with serious symptoms, it can be considered to be combined with clozapine.

参考文献/References:

[1]陈生第. 中华医学会神经病学分会帕金森病及运动障碍障碍学组. 中国帕金森病治疗指南(第三版)[J]. 中华神经科杂志, 2014, 47(6): 428-433.
[2]Huang X, Yang J, Yang S, et al. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms[J]. Oncotarget, 2017, 8 (60): 102705-102720.
[3]Haleem DJ. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia[J]. Behavioural pharmacology, 2015, 26 (1-2 ): 45-58.
[4]Bezard E, Munoz A, Tronci E, et al. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia[J]. Neurosci Res, 2013, 77(4): 242-246.
[5]Ko WKD, Li Q, Cheng LY, et al. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson’s disease[J]. Eur J Pharmacol, 2017, 813(10): 10-16.
[6]Ku S, Glass GA. Age of Parkinson’s disease onset as a predictor for the development of dyskinesia[J]. Mov Disord, 2010, 25(9): 1177-1782.
[7]Nevalainen N, Af Bjerkén S, Gerhardt GA, et al. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia[J]. Neuroscience, 2014, 260: 73-86.
[8]Sebastianutto I, Cenci MA. MGlu receptors in the treatment of Parkinson’s disease and L-DOPA-induced dyskinesia[J]. Curr Opin Pharmacol, 2018,38:81-89.
[9]Lanza K, Bishop C. Serotonergic targets for the treatment of L-DOPA-induced dyskinesia[J]. J Neural Transm (Vienna), 2018, 125 (8): 1203-1216.
[10]Picconi B, De Leonibus E, Calabresi P. Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities[J]. J Neural Transm (Vienna), 2018, 125 (8): 1263-1271.
[11]Schaeffer E, Pilotto A, Berg D, et al. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson’s disease[J]. CNS Drugs, 2014, 28 (12): 1155-1184.
[12]Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs[J]. J Clin Invest, 2013, 123(12): 4986-4991.
[13]龙忠芳, 刘程曦, 喻田. 中缝背核5-羟色胺能神经通路功能研究进展[J]. 医学研究生学报, 2020, 33(2): 197-200.
[14]McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors[J]. Pharmacol Ther,2015, 150: 129-142.
[15]Yuan S, Peng Q, Palczewski K, et al. Mechanistic studies on the stereoselectivity of the serotonin 5-HT1A receptor[J]. Angew Chem Int Ed Engl, 2016, 55(30): 8661-8665.
[16]Stroth N, Niso M, Colabufo NA, et al. Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of β-arrestin-2[J]. Bioorg Med Chem, 2015, 23 (15): 4824-4830.
[17]宁征远, 谢姗姗, 李健, 等. 阿戈美拉汀联合坦度螺酮对老年抑郁症患者血清NE、5-HT水平的影响[J].东南国防医药, 2017, 19(3): 251-253.
[18]Iderberg H, McCreary AC, Varney MA, et al. Activity of serotonin 5-HT(1A) receptor ’biased agonists’ in rat models of Parkinson’s disease and L-DOPA-induced dyskinesia[J]. Neuropharmacology, 2015, 93(9): 52-67.
[19]Kannari K, Kurahashi K, Tomiyama M, et al. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s disease[J]. Brain Nerve, 2002, 54(2): 133-137.
[20]林秀洁, 黄传礼, 王志坚. 坦度螺酮联合恩他卡朋治疗帕金森病异动症的疗效[J]. 中国老年学杂志, 2018, 9(38): 4460-4462.

相似文献/References:

[1]胡 晓,王 省,闫福岭,等.帕金森病患者便秘发生情况的临床观察[J].医学研究与战创伤救治(原医学研究生学报),2013,15(04):332.[doi:10.3969/j.issn.1672-271X.2013.04.004]
　HU Xiao,WANG Xing,YAN Fu-ling,et al.Clinic investigation of constipation in Parkinson's disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(02):332.[doi:10.3969/j.issn.1672-271X.2013.04.004]
[2]于苏文,郑秀琴,陈红霞,等.高频重复经颅磁刺激治疗帕金森病临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2010,12(02):109.
　YU Su-wen,ZHENG Xiu-qin,CHEN Hong-xia,et al.Clinicalal study of treating Parkinsons disease by repetitively transcranial magnetic stimulation[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(02):109.
[3]曾 志,张国兴,陈基敏.代谢热层像诊断帕金森病5例报告[J].医学研究与战创伤救治(原医学研究生学报),2008,10(01):6.
[4]余志阳,潘士勇,刘清珍,等.丙泊酚对帕金森小鼠黑质多巴胺能神经元凋亡的影响[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):346.[doi:10.3969/j.issn.1672-271X.2015.04.003]
　YU Zhi-yang,PAN Shi-Yong,LIU Qing-zhen,et al.The effect of propofol on apoptosis of dopaminergic neurons in the substantia nigra of mouse model of Parkinson’s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):346.[doi:10.3969/j.issn.1672-271X.2015.04.003]
[5]张扬,管得宁,徐运.跌倒恐惧对帕金森病患者生活质量的影响[J].医学研究与战创伤救治(原医学研究生学报),2018,20(01):6.[doi:10.3969/j.issn.1672-271X.2018.01.002]
　ZHANG Yang,GUAN De-ning,XU Yun.Impact of fear of falling on quality of life in patients with Parkinson′s disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(02):6.[doi:10.3969/j.issn.1672-271X.2018.01.002]
[6]戴为正,吴美娜,傅懋林,等.普拉克索联合高频重复经颅磁刺激治疗早期帕金森病合并抑郁患者的临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):592.[doi:10.3969/j.issn.1672-271X.2021.06.007]
　DAI Wei-zheng,WU Mei-na,FU Mao-lin,et al.Observation on clinical effects of pramipexole combined with high-frequency repetitive transcranial magnetic stimulation (rTMS) in the treatment of patients suffered from early Parkinson’s disease (PD) and depression[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(02):592.[doi:10.3969/j.issn.1672-271X.2021.06.007]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-03-22